Evidence map›Paper›PMID 34195327›Full record

ArticleJAAD case reports2021

Drug-induced hypersensitivity syndrome like reaction with angioedema and hypotension associated with BRAF inhibitor use and antecedent immune checkpoint therapy.

Jasmine Rana, Nolan J Maloney, Kerri E Rieger, Silvina B Pugliese, Jenna L Strelo, Anne Liu, Lisa C Zaba, Bernice Y Kwong

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in JAAD case reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jasmine RanaDepartment of Dermatology, Stanford University Medical Center and Cancer Institute, Palo Alto, California.
Nolan J MaloneyDivision of Dermatology, Department of Medicine, David Geffen School of Medicine, The University of California, Los Angeles, California.
Kerri E RiegerDepartment of Dermatology, Stanford University Medical Center and Cancer Institute, Palo Alto, California.
Silvina B PuglieseDepartment of Dermatology, Stanford University Medical Center and Cancer Institute, Palo Alto, California.
Jenna L StreloDepartment of Dermatology, Stanford University Medical Center and Cancer Institute, Palo Alto, California.
Anne LiuDepartment of Dermatology, Stanford University Medical Center and Cancer Institute, Palo Alto, California.
Lisa C ZabaDepartment of Dermatology, Stanford University Medical Center and Cancer Institute, Palo Alto, California.
Bernice Y KwongDepartment of Dermatology, Stanford University Medical Center and Cancer Institute, Palo Alto, California.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BRAFBRAFi, BRAF inhibitorsBRAF inhibitorCTLA4dabrafenibDIHSDIHS, drug-induced hypersensitivity syndromeDLR, DIHS-like reactionDRESSencorafenibICIICI, immune checkpoint inhibitorimmune checkpoint therapyimmune related adverse effectirAEircAEoncodermPD-1PD1PD-L1rashTT, targeted therapyvemurafenib

Identifiers

PMID34195327
PMCPMC8234355

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.